Henry C. Marsh

72 year

Health Technology

Profile

Henry C.
Marsh, Jr. joined AVANT Immunotherapeutics, Inc. in 1986 as Senior Scientist and has been Vice President of Research since May 1998.
Prior to joining AVANT, he was employed as a Scientist at Abbott Laboratories of North Chicago and the Research Triangle Institute in North Carolina.

Former positions of Henry C. Marsh

Companies	Position	End
AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA.	Corporate Officer/Principal	30/09/2008

See the detail of Henry C. Marsh's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Henry C. Marsh's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA.	Health Technology